
Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus
Keywords: Type 2 diabetes mellitus (T2DM); Glucokinase activator (GKA); GK; glucokinase; GKA; glucokinase activator; SU; sulfonylurea; DPP-4; dipeptidyl peptidase-4; TZD; thiazolidinedione; SGLT2; sodium-glucose co-transporter 2; GSIS; glucose-stimulated insulin se